# Neutralizing antibody titers predict protection from virus transmission in a cohort of household members with documented exposure to SARS CoV-2

- 4 Henrike Maaβ<sup>1,2</sup>, Imke Hinrichs<sup>3</sup>, Martina Pavletic<sup>4,5</sup>, Manuela Harries<sup>6</sup>, Tatjana Prinke<sup>1,2</sup>, Najat Bdeir<sup>1,2</sup>,
- 5 Richard Egelkamp<sup>7</sup>, Berit Lange<sup>6,8</sup>, Yannic C Bartsch<sup>3</sup>, Mate Lerga<sup>4,5,#</sup>, Luka, Cicin-Sain<sup>1,2,8, #,\*</sup>
- 6 <sup>1</sup> Department of Viral Immunology, Helmholtz Center for Infection Research, Braunschweig, Germany
- <sup>2</sup> Centre for Individualised Infection Medicine (CiiM), a joint venture of Helmholtz Centre for Infection Research and Hannover
   Medical School, Hannover, Germany
- 9 <sup>3</sup> Laboratory of Anti-viral antibody-omics, TWINCORE-Institute for Experimental Infection Research, Helmholtz Center for
- 10 Infection Research (HZI) and Medical School Hannover (MHH), Hannover, Germany.
- <sup>4</sup> Emergency Department, Clinical Hospital Center Rijeka, Rijeka, Croatia
- <sup>5</sup> Department for anesthesiology, reanimatology, emergency and intensive care medicine, Medical Faculty Rijeka, Rijeka, Croatia
- <sup>6</sup> Department of Epidemiology, Helmholtz Center for Infection Research, Braunschweig, Germany
- <sup>7</sup> Public Health Agency of Lower Saxony (NLGA), Hannover, Germany
- <sup>8</sup>German Centre for Infection Research (DZIF), partner site Hannover/Braunschweig, Braunschweig, Germany
- <sup>#</sup> These authors jointly supervised this work
- 17 <sup>\*</sup> Correspondence: luka.cicin-sain@helmholtz-hzi.de

#### 18 Abstract

#### 19 Background

- 20 While correlates of protection against symptomatic and severe breakthrough SARS-CoV-2 infections are
- 21 well characterized, correlates of protection against virus transmission are incompletely understood.

# 22 Methods

- 23 We studied a Croatian cohort of individuals with documented household exposure to SARS-CoV-2 in
- 24 December 2022. Sera were acquired prior to symptom onset, at the time of the COVID-19 diagnosis of
- the index cases, and comprehensively analyzed for correlates of protection against virus transmission. We
- 26 monitored participants for 14 days and tested them with PCR at the end of the observation period to
- 27 identify any virus transmission, including asymptomatic ones.

#### 28 Interpretation

- Out of nearly 200 tested serological parameters, 22 features were significantly different between the infected and the uninfected participants. Titers of variant-specific neutralizing antibody showed the
- 31 biggest difference and were significantly higher in the uninfected subgroup. Some infected individuals
- 52 Siggest anterenee and were significantly ingher in the animeted subgroup. Some intereted marriadals
- 32 with strong IgM responses to the spike antigen showed robust neutralization titers as well. Since IgM is
- 33 likely an indication of recent antigenic exposure, data were reanalyzed by excluding such values. This

It is made available under a CC-BY 4.0 International license .

refined analysis showed a complete segregation of infected and uninfected individuals into groups with low and high variant-specific neutralization titers. Therefore, our data indicate that high neutralizing titers are correlates of protection against SARS-CoV-2 transmission in intense contacts among household members.

# 38 Funding

39 This research was funded by the Impulse and Networking fund of the Helmholtz Association through the

40 grant PIE-0008 to LCS and VH-NG-19-28 to YCB and by the Deutsche Forschungsgemeinschaft (DFG,

41 German Research Foundation) under Germany's Excellence Strategy - EXC 2155 - project number

42 390874280 to LCS. BL and MH received funding within the RESPINOW project from the Federal

43 Ministry of Education and Research under the grant number 031L0298A.

44

### 45 Keywords

46 SARS-CoV-2, COVID-19, vaccine, neutralizing antibodies, correlate of protection

It is made available under a CC-BY 4.0 International license .

# 48 **Research in Context**

# 49 Evidence before this study

50 Pre-existing immunity to SARS-CoV-2, whether from prior infections or vaccinations, has been shown to 51 primarily protect against severe disease rather than preventing infection altogether. Many current studies 52 examining this phenomenon focus on cohorts with breakthrough infections occurring a certain time after 53 their last vaccination. However, these studies often lack precise information about when the individuals 54 were infected and their serological status immediately before the infection.

# 55 Added value of this study

56 Unlike other studies, we focused on a cohort of individuals with a confirmed SARS-CoV-2-positive 57 household member. Serum samples were collected before symptom onset, coinciding with the COVID-19 58 diagnosis of the index cases. We analyzed various serum features to comprehensively assess their ability 59 to protect not only against severe disease but also against virus transmission. Our findings revealed that 60 individuals who remained uninfected had significantly higher concentrations of neutralizing antibodies 61 compared to those who became infected.

# 62 Implications of the available evidence

This finding suggests that neutralizing antibodies serve as a correlate of protection against virus transmission and could inform booster strategies based not on a fixed timeline but on antibody levels dropping below a specific threshold. However, due to the limited sample size of our study, larger studies are needed to confirm these results and establish an exact threshold.

It is made available under a CC-BY 4.0 International license .

## 67 **1. Introduction**

The coronavirus disease that emerged in December of 2019 (COVID-19), caused by the Severe Acute 68 69 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has had a profound impact on public health, 70 leading to widespread infections, disease and death. The establishment of herd immunity due to the 71 spread of infections and global vaccine campaigns has led to a reduction in severe symptoms. However, 72 infection with SARS-CoV-2 can still result in long-term complications, known as long COVID, regardless of the initial severity of the disease (1), and vulnerable populations, such as the 73 74 immunocompromised or the elderly, remain at risk of severe disease courses. Anti-COVID vaccines 75 prevent severe disease, yet their effectiveness against symptomatic infections and milder disease courses 76 wane relatively quickly (2). As a result, vaccination recommendations are primarily focused on 77 individuals at higher risk of developing severe COVID-19, such as the elderly, immunocompromised 78 individuals, and those working with vulnerable populations (3). Preventing infections in general, not just 79 severe disease, should remain important in light of the risk of long COVID, which is common even upon 80 less severe acute episodes, as it has been shown that vaccination reduces the risk of long COVID as well 81 (4).

82 Since the development of SARS-CoV-2 vaccines, correlates of protection (CoP) have been studied to 83 assess vaccine efficacy. Early research identified neutralizing antibodies (nAbs) as key CoPs against 84 symptomatic disease induced by both vaccination and infection (5-7). However, no CoP or threshold 85 levels have been established to guide recommendations on protection against infection, and hence, transmission. Therefore, national advisory bodies provide widely divergent guidelines on booster 86 87 vaccination schedules. Most studies investigating CoPs have merely provided estimates based on the time since last vaccination, without knowing the exact time or circumstances of participants' exposure to 88 89 SARS-CoV-2 or objective criteria to quantify immune responses (8, 9). However, there are few studies 90 assessing the role of serological parameters predicting the protection against virus transmission, 91 especially in light of the rapidly evolving variants of SARS-CoV-2.

92 In this study, we examined households where one individual (the index case) tested positive for SARS-93 CoV-2 in the emergency department of the Clinical Hospital Center Rijeka, Croatia, during the winter of 94 2022/2023 to estimate the protection of transmission within the household using serological parameters 95 and neutralizing antibodies. Household members were tested at an initial time point shortly after the index 96 case and again 14 days later, or earlier if they developed COVID-like symptoms within two weeks. Based 97 on their SARS-CoV-2 status during this period, household members were categorized into SARS2 98 positive and those that remained SARS2 negative throughout the analysis period and comprehensively 99 analyzed to identify differences in serum parameters between those two groups. Variant specific nAbs,

It is made available under a CC-BY 4.0 International license .

- along with various other serum features were the best predictor of protection against virus transmission,
- 101 while vaccination status and the timing of the last immunogenic event were non-significant as predictors
- 102 of protection against breakthrough infections.

It is made available under a CC-BY 4.0 International license .

# 103 2. Material and Methods

# 104 2.1 Study participants and Study design

105 This study included household members of individuals who tested positive for SARS-CoV-2. Citizen who 106 experienced SARS-CoV-2-like symptoms were tested in the Emergency department of the Clinical 107 Hospital Center Rijeka. Household members (older than 18 years) of people who appeared SARS-CoV-2 108 positive in routine screenings were asked to visit the hospital within 48 h. Index (n=18) and household 109 contacts (n=20) were tested via nasopharyngeal swab, by rapid test (Hangzhou AllTest Biotech Co., Ltd) 110 as well as a fast RT-qPCR, essentially as described (10), to determine the SARS-CoV-2 status. 111 Additionally, a blood sample was obtained. The household members who were SARS-CoV-2 negative at 112 the first time-point (n=12 at 48 h) were asked to come back after 14-days or in between if they experience 113 symptoms to get tested a second time. A schematic overview of the study design can be seen in Figure 1 114 and Figure S1. The recruitment of participants occurred in December 2022.

# 115 2.2 Sample preparation

116 Nasal swab samples were either stored at 4°C for immediate usage or aliquoted and stored at -80°C. The 117 variant by which the index person was infected was identified by next generation sequencing (NGS) using 118 the NEBNext ARTIC SARS-CoV-2 FS Library Prep Kit for Illumina with VarSkip 2b primers (New 119 England Biolabs, MA, USA. Paired-end sequencing was performed on an Illumina NextSeq 1000 120 (Illumina, CA, USA). For assembly, CoVpipe v3.1.0 (Robert Koch-Institut, Germany; 121 https://www.gitlab.com/RKIBioinformaticsPipelines/ncov minipipe) was used with standard parameters, 122 while lineage assignment was done with pangolin v4.3 and pangolin-data v1.21 (11). Whole blood 123 samples were incubated for 30-60 min at room temperature. Serum and blood clot were separated by 124 centrifugation at 1500 g for 10 min. The supernatant was aliquoted and stored at -80 °C. The samples 125 were shipped on dry ice to the Helmholtz Center for Infection Research in Braunschweig for further 126 analyses.

### 127 2.3 Demographic data and outcomes

Demographic data of all participants is listed in Table 1. Data was obtained through questionnaires, whichwere asked at the first and second sampling date either in person or through follow-up phone calls.

# 130 2.4 Neutralization Assay

Neutralization assays were performed according to previously published protocol (12). The serum samples were heat inactivated at 56 °C and 500 rpm for 30 minutes and afterwards 1:10 diluted in DMEM (1% Penicillin-Streptomycin, 1% L-Glu, 5% FBS) and stored at 4 °C or -80 °C for long-term storage. Sera were two-fold diluted in a 96 well plate ranging from 1:100 to 1:102400 and incubated with pseudovirus particles (600 pfu  $\pm$  30%) for one hour at 37°C. A control showing no inhibition by incubation in

It is made available under a CC-BY 4.0 International license .

the absence of serum was used. Serum-virus samples were transferred to a VeroE6 96 well plate (80% 136 confluent) and further incubated at 37 °C for 24 hours after which the plates were fixed with 4% 137 paraformaldehyde (PFA) and kept at 4 °C until readout. To count GFP<sup>+</sup> infected cells, the IncuCyte S3 138 139 (Sartorius) was used by performing whole-well scans (4x magnification) in phase contrast and green 140 fluorescence settings (300 ms exposure). The IncuCyte GUI software (version 2019B Rev1 and 2021B) 141 performed automated counting of GFP fluorescent foci. The pseudo-virus neutralization titer 50 142 (PVNT50) was calculated by non-linear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non-responders were given a PVNT50 of 25 for visualization purposes. 143

# 144 2.4.1 IgM depletion in serum samples

For certain experiments, only the IgG fraction of the nAbs was supposed to be measured. Therefore, IgM was depleted using beta-mercaptoethanol (2-ME) on heat-inactivated serum (13). Serum was incubated with 2-ME (final concentration of 140 mM) for 1h at room temperature and 300 rpm. Afterwards, the serum was diluted 1:10 with DMEM (1% Penicillin-Streptomycin, 1% L-Glu, 5% FBS) and immediately used for neutralization assays.

150 2.4.2 SARS-CoV-2 specific IgM and IgG ELISA

To validate the efficiency of the IgM depletion by 2-ME, an enzyme-linked immunosorbent assay (ELISA) was performed. Therefore, serum was treated with 2-ME as explained before and the Human SARS-CoV-2 Spike (Trimer) IgM ELISA Kit (#BMS2324, Invitrogen, Waltham, United States) and Human SARS-CoV-2 Spike (Trimer) IgG ELISA Kit (#BMS2325, Invitrogen, Waltham, United States) were performed as per manufacturer's instructions. The assay was run on exemplary participants with high, medium and low IgM based on the Luminex assay, in technical duplicates. The Infinite® F50 (Tecan, Männedorf, Switzerland) was used for readout of the ELISA plates.

# 158 2.5 Detection of antigen-specific antibody isotypes and Fc-receptor binding

Human serum samples were profiled for antigen-specific antibody isotypes and binding of Fcy receptors 159 160 with a custom antigen panel as previously described (14). Recombinant antigens were obtained 161 commercially (Sino Biological, Beijing, China). The custom antigen panel consisted of recombinant 162 SARS-CoV-2 trimeric spikes (D614G, B1.1.529 and BA.4/BA.5/BA.5.2), receptor binding domain 163 (RBD) (D614G, B1.1.529 and BA.4/BA.5/BA.5.2), N-terminal domain (NTD) (2019-nCoV), 164 nucleocapsid (NC) (2019-nCoV), S1 (D614G) and S2 domains (2019-nCoV), the trimeric spike of the 165 human coronaviruses HKU1 (N5) and OC43, and the respiratory syncytial virus (RSV) prefusion protein 166 (preF). For the Luminex assay, 10 µg antigen were covalently coupled to 2 million carboxylated magnetic microspheres (Diasorin, Italy) by carboxy-coupling as described before (14). 167

It is made available under a CC-BY 4.0 International license .

Serum samples were diluted with assay buffer (PBS, 0.1% BSA) depending on detector to 1:500 for 168 169 IgG1, 1:100 for IgG2-4, IgA1-2 and IgM, and 1:1000 for the Fcy receptors. In a 384-well plate, 5 µL of 170 diluted sample were incubated overnight with a pool of the antigen-coupled microspheres (1,000 beads 171 per antigen per well) at 4 °C. Plates were washed three times with PBS-T (PBS, 0.05% Tween-20) and 172 incubated for 1 h with 40 µL of PE-conjugated secondary detector (1µg/ml) against IgG1 173 (RRID: AB\_2796628), IgG2 (RRID: AB\_2796639), IgG3 (RRID: AB\_2796701), IgG4 174 (RRID: AB 2796577), IgA1 (RRID: AB 2796656) (RRID: AB 2796693), IgM and IgA2 175 (RRID: AB 2796664) (all Southern Biotech, AL, USA). To detect Fc receptor interaction, streptavidin-176 PE:biotin-coupled FcyRIIa (H167), FcyRIIa (R167), FcyRIIb/c, FcyRIIIa (F176), FcyRIIIa (V176), 177 FcyRIIIb (NA1) and FcyRIIIb (NA1) (all AcroBiosystems, DE, USA) were used (1 µg/mL). Upon 178 incubation, immune complexes were washed three times with PBS-T using the HydroSpeed automated 179 plate washer (Tecan, Switzerland), resuspended in assay buffer and acquired at the ID7000 Spectral Cell 180 Analyzer (Sony Biotechnology, CA, USA).

# 181 2.6 Biotinylation and bead-coupling of antigens

For antibody-dependent complement deposition (ADCD), antibody-dependent THP-1 cell-phagocytosis (ADCP) and antibody-dependent neutrophil-phagocytosis (ADNP), the spike trimers of wild-type SARS-CoV2 (D614G) and Omicron variant BA.4/5 were biotinylated using the NHS-Sulfo-LC-LC kit (Thermo Fisher, MA, USA) according to the manufacturer's instructions. After the reaction, excess biotin was removed by size exclusion using Zeba spin desalting columns with a 7 kDa cut-off (Thermo Fisher). 10  $\mu$ g of biotinylated antigen was coupled to 10  $\mu$ l of 1.0  $\mu$ m NeutrAvidin-labelled microspheres for 2 h at 37 °C.

# 189 2.7 Antibody-dependent complement deposition (ADCD)

The ability of antigen-specific antibodies in the human serum samples to induce the complement cascade 190 191 was assessed as described before (15). Briefly, immune complexes were formed in a 96-well round 192 bottom plate by incubating antigen-coated microspheres with 10 µL of 1:10 diluted human serum samples 193 for 2 h at 37 °C. Reconstituted guinea-pig complement (Cedarlane, ON, Canada) was cleared by 194 centrifugation, transferred to GVB++ buffer (Novateinbio, MA, USA) and incubated with washed 195 immune complexes for 20 min at 37 °C and 5% CO<sub>2</sub>. Complexes were then washed once with 15 mM 196 EDTA in PBS. Deposited C3 on beads was stained with 1:100 diluted anti-guinea pig C3a-FITC antibody 197 (MP Biomedicals, CA, USA) and afterwards fixed with 4% paraformaldehyde (PFA). C3 deposition was 198 then determined as mean fluorescent intensity (MFI) on an ID7000 Spectral Cell Analyzer (Sony 199 Biotechnology).

It is made available under a CC-BY 4.0 International license .

# 200 2.8 Antibody-dependent neutrophil-phagocytosis (ADNP)

Neutrophil-mediated phagocytosis of serum antibodies was determined as previously described (16). 201 202 Antigen-coated yellow-green fluorescent microspheres were incubated with 10 µL of 1:50 diluted human 203 serum for 2 h at 37 °C and 5% CO2. Primary neutrophils were obtained by lysis of whole blood with 204 Ammonium-Chloride-Potassium (ACK) buffer (Biomol, Germany) and transferred to R10 media (RPMI 205 1640, 10% FCS, 1x GlutaMax, 1x Penicillin-Streptomycin, 10 mM HEPES). The immune complexes 206 were washed by centrifugation and incubated with 50,000 neutrophils for 1 h at 37 °C and 5% CO<sub>2</sub>. Next, 207 neutrophils were stained with 1:100 diluted anti-human CD66b-Pacific Blue antibody (BioLegend, CA, 208 USA, RRID: AB 2563294) and fixed with 4% PFA for 20 min. Phagocytic activity of neutrophils was 209 measured on an ID7000 Spectral Cell Analyzer (Sony Biotechnology). A phagocytosis score was 210 calculated as product of frequency bead positive neutrophils and the MFI of bead positive neutrophils.

# 211 2.9 Antibody-dependent THP-1 cell-phagocytosis (ADCP)

The level of serum antibody-induced phagocytic activity of THP-1 monocytes was detected as previously described (5). In brief, antigen-coated yellow-green fluorescent microspheres were combined with  $10 \,\mu$ L of 1:100 diluted human serum in a 96-well round bottom plate and incubated for 2 h at 37 °C and 5% CO2. Next, 25,000 cultured THP-1 cells (#ACC 16, DSMZ, Germany) in R10 media were added and incubated overnight at 37 °C and 5% CO<sub>2</sub>. THP-1 cells were then fixed with 4% PFA for 20 min, washed and resuspended in PBS prior to acquisition on an ID7000 Spectral Cell Analyzer (Sony Biotechnology). A phagocytosis score was calculated for THP-1 monocytes in the same way as for neutrophils.

# 219 2.10 Antibody-dependent NK cell-activation (ADNKA)

220 To investigate antibody-mediated NK cell activation, 96-well flat bottom high-binding plates were coated 221 with 50 µL (3 µg/mL) of either the spike trimer of wild-type SARS-CoV2 (D614G) or Omicron variant 222 BA.4/5. After blocking with 5% BSA-PBS for 2 h, 50 µL of 1:30 diluted human serum samples were 223 added and incubated overnight at 4 °C. Primary NK cells were derived from leukocyte reduction cones of 224 healthy donors using the RosetteSep NK cell enrichment kit (STEMCELL Technologies, MA, USA) 225 according to the manufacturer's instructions followed by density gradient centrifugation. The enriched 226 cells were then stimulated with 1 ng/mL of recombinant human IL-15 (BioLegend) overnight at 37 °C 227 and 5% CO2. After washing the immune complexes three times, 50,000 NK cells were added to each well 228 and incubated with 2 µg Brefeldin A (Sigma Aldrich, MA, USA), 1:80 GolgiStop (BD Biosciences, NJ, 229 USA) and 1:11 diluted anti-human CD107a-BV605 (BioLegend, RRID: AB\_2563851) for 5 h at 37 °C 230 and 5% CO2. To define NK cells as CD3-CD56+, the cells were stained for 15 min with 1:40 diluted anti-231 human CD3-APC-Cy7 (BioLegend, RRID: AB\_830755) and 1:20 diluted anti-human CD56-PE-Cy7 (BioLegend, RRID: AB\_2857328). After fixation and permeabilization with fixation medium 232 233 (Invitrogen) and permeabilization medium (Invitrogen), respectively, NK cells were stained

It is made available under a CC-BY 4.0 International license .

intracellularly with 1:200 anti-human MIP-1 $\beta$ -BV421 (BD Biosciences, RRID: AB\_2737877) and 1:50 anti-human IFN- $\gamma$ -PE (BioLegend, RRID: AB\_315440) for 15 min. Finally, samples were washed, resuspended in PBS and the MFI of extracellular and intracellular markers acquired on an ID7000 Spectral Cell Analyzer (Sony Biotechnology).

238 2.11 Statistical analysis

Due to small sample size, all data was log10-transformed and analyzed using parametric tests. For group
 comparison, an unpaired t-test with Welch's correction was performed. Data representation and statistical

- analysis was done using R software v4.3.2 or GraphPad Prism v10.2.2 (GraphPad Software, CA, USA).
- 242 2.12 Ethical Considerations

243 The Institutional Review Board of the Rijeka Clinical Hospital Center (2170-29-02/1-22-2) as well as the

Hanover Medical School (10783\_BO\_K\_2023) approved this study. Written informed consent was

obtained from all participants.

It is made available under a CC-BY 4.0 International license .

# **3. Results**

248 3.1 Demographic and clinical characteristics of study population

This study was conducted at the Clinical Hospital Center Rijeka, focusing on households in which one member tested positive for SARS-CoV-2 (from now on called index person). Household members donated a blood sample within 48 h after the index person was tested. The samples were analyzed, categorizing the household members based on whether they contracted the infection within 14 days after the initial sampling or remained uninfected. A schematic study overview can be seen in Figure 1 and Figure S1.



255

Figure 1: Brief schematic study overview. Household members of SARS-CoV-2 positive index persons donated a serum sample (t=0) at the Clinical Hospital Center Rijeka, 48 h after confirmation of the infection of the index person. Within 14 days, the household members were asked to report if COVID-19 like symptoms appeared or were asked to come back after two weeks to be tested by rapid test and qPCR. Serology features were determined using various assays. Created with BioRender.com.

261 The study cohort consisted of 18 index people and 20 household members. Half of the household 262 members (n=10) remained negative over the 14 day study period (from now on called not-infected or negative group). Eight household members were SARS-CoV-2 positive at the initial testing and two were 263 infected within the 14 days (these 10 participants will be referred to as infected or positive group). Both 264 groups presented similar characteristics, which can be seen in Table 1. In summary, both groups showed 265 266 no significant differences in terms of number of vaccinations or days since last vaccination or latest 267 immunogenic event (i.e., vaccination or natural infection). The non-infected group presented non-268 significantly higher number of participants with a previous COVID disease.

It is made available under a CC-BY 4.0 International license.

#### 269 Table 1: Demographic data of household members included in this study, separated by the 14 day SARS-270 CoV-2 status.

	Household members (n=20)		
Number of household members [median]	2 (2-3)		
COVID-19 qPCR Test	Positive (n=10)	Negative (n=10)	р
Female [%]	20	30	ns <sup>a</sup>
Number of Vaccinations [median, p25-75]	2.5 (1.75-3)	2 (2-3)	ns <sup>b</sup>
Days from latest vaccination until first test [median, p25- 75]	374 [341-475.5]	409 [339-536.5]	ns <sup>b</sup>
prior COVID-19 infection	4	7	ns <sup>a</sup>
Days from latest immunnogenic event until first test [median, p25-75]	347 [338.5-387]	312 [192.5-425.5]	ns <sup>b</sup>
Number of comorbidities	1 [0-2.25]	0.5 [0-1.25]	ns <sup>b</sup>

271

<sup>a</sup> Calculated by Fisher's exact test. <sup>b</sup> Calculated by unpaired t test. ns = non-significant

3.2 Not-infected household members show multiple differently expressed features of 272 273 adaptive humoral immunity

274

275 We quantified various features of spike-specific humoral immunity in the initial serum samples, including 276 a systems serology approach, levels of antibodies targeting different virus epitopes as well as different 277 SARS-CoV-2 variants and respiratory viruses like RSV (Table S1). Additionally, nAbs targeting different 278 SARS-CoV-2 spike strains were analyzed. Out of 198 features, 21 were significantly upregulated in the 279 negative group, compared to the positive and one downregulated in the negative group (Figure 2a). 280 Amongst those, seven features were IgG1 binding titers, targeting different SARS-CoV-2 epitopes or 281 strains and four were related to binding of IgA1 antibodies. Additionally, the nAb concentrations against 282 all tested SARS-CoV-2 strains were increased in the not-infected group. Figure 2b shows the log-283 transformed levels of the 22 differently expressed features.

284 As some participants presented high IgG1 levels, which is usually the most dominant IgG subclass, we 285 normalized the data by the IgG1 signal of uninfected and infected groups to see whether there are 286 mechanistic differences in FcgR binding, Fc function or neutralization (Figure 2c). We identified Fc-287 mediated effector functions and the virus neutralizing titers (VNT) to be more robust in uninfected

It is made available under a CC-BY 4.0 International license .

participants, which is in line with the findings of Figure 2b and c, and highlights the importance of nAbsas CoP.





It is made available under a CC-BY 4.0 International license .

dots represent non-significant features. Blue dots indicate features significantly upregulated in positive household members, while red dots represent features significantly upregulated in negative household members. b) A heatmap illustrating the significantly differentially expressed features identified in the volcano plot. Feature levels were logtransformed. Each column corresponds to a participant, and each row represents feature levels. Column annotations denote the condition of each participant. Clustering was performed based on Euclidean distance. c) Heatmaps of normalized average IgG1 corrected values (feature/IgG1) for each feature are shown for spike trimers and RBD of WT (D614G) and Omicron BA.4.5, comparing infected (n=10) to non-infected (n=10) individuals. Data from Luming head ensure. ADCD and wing neutraligation essays were heald teneformed reight to IgC1 according

- 301 Luminex bead assays, ADCD and virus neutralization assays were log10 transformed prior to IgG1 normalization.
- 302
- 303 3.3 nAb as correlate of protection

To further investigate the importance of nAbs, we individually analyzed their concentrations. All concentrations were elevated in participants who did not get infected (Figure 3a) even against the original Wuhan strain, which by the time of sampling was not present anymore. Interestingly, the closer the tested strains got to the strain by which the index person was infected and to the at that time circulation variant BA.4/5, the more prominent the difference appeared. By looking at their prognostic potential with a receiver operation characteristic (ROC) curve, all measured nAb concentrations showed significance (Wuhan p = 0.028; BA.1 p=0.0191; BA.4/5 p=0.0156; closest strain (c.s.) p=0.0091) (Figure 3b).



Figure 3. Neutralizing antibody concentrations in household members at initial sampling. a) Neutralizing antibody (nAb) concentrations were measured using pseudovirus neutralization assays against SARS-CoV-2 spike variants Wuhan, Omicron BA.1, and BA.4/5, as well as a relatively closely related strain. Participants were categorized as not infected (grey dots) or infected (purple squares). The dotted line indicates the limit of confidence. For analysis, the data was log-transformed and a t-test with Welch's correction was conducted. The black line

It is made available under a CC-BY 4.0 International license .

represents the median for each group. b) ROC analysis of nAb concentrations, with the area under the curve shown in the plot. \* = p < 0.05.

319 3.4 IgM-high participants screw protection potential of nAb

320 As the majority of our infected participants were already SARS-CoV-2 positive at the initial time point, 321 we expected high IgM levels in some of them, limiting our ability to mainly analyze the nAb fraction 322 which was present before the exposure. Hence, we checked the IgM levels targeting the nucleocapsid of 323 the household members to identify outliers with very high IgM. In Figure 4 we show the levels being not 324 significantly different between the two groups. Nevertheless, we identified three outliers (one in the non-325 infected, two in the infected) which had extremely elevated IgM in contrast to the rest of their respective 326 group. We compared the neutralizing activity after excluding these participants with outlier IgM levels as 327 they might have had a previous infection and their results would not be in line with the other participants. 328 The significance of all variants increased drastically, separating the concentration of both groups clearly 329 (Figure 4b). Moreover, the ROC analysis emphasize what impact those outliers have on the predictability 330 of this feature (Wuhan p=0.0021; BA.1 p=0.0015; BA.4/5 p=0.0005; c.s. p=0.0008) (Figure 4c). 331 Additionally, by using 2-ME, we were able to eliminate IgM out of the serum (13). We validated the

results by ELISA (Figure S2a) confirming that IgM was depleted with modest effect on IgG concentrations. Next, all pseudovirus neutralization assays were repeated with 2-ME treated serum (Figure S2b). However, the difference between the two groups did not drastically increase and in the case of the closest strain even decreased (ROC Wuhan p=0.0284; BA.1 p=0.0233; BA.4/5 p=0.0156; c.s. p=0.0233). Interestingly, individuals with initial los neutralizing captivity showed increased neutralization upon IgM depletions.

Lastly, we repeated the normalization by IgG1 as shown before but excluded the three IgM high participants, and saw even more prominent Fc-mediated effector functions and VNT responses in uninfected participants (Figure 4d). This summarizes the overall finding of nAbs being one of the most important CoP.

It is made available under a CC-BY 4.0 International license .



344 Figure 4. nAb concentration without IgM outliers. a) IgM levels against the SARS-CoV-2 nucleocapsid were 345 measured using Luminex. Participants were categorized as not infected (grey dots) or infected (purple squares). One 346 participant in the not infected group (red dot) and two outlier in the infected group (red squares) presented a high 347 IgM level. A t-test with Welch's correction was conducted for analysis. b) Participants were categorized as not 348 infected (grey dots) or infected (purple squares), participants with high IgM were excluded for the analysis. The 349 dotted line indicates the limit of confidence. For analysis, the data was log-transformed, and a t-test with Welch's 350 correction was conducted. The black line represents the median for each group. c) ROC analysis of nAb 351 concentrations, with the area under the curve shown in the plot. d) Heatmaps of normalized average IgG1 corrected 352 values (feature/IgG1) for each feature are shown for spike trimers and RBD of WT (D614G) and Omicron BA.4.5, 353 comparing normalization including IgM-high participants (left) to exluding IgM-high participants (right). Data from 354 Luminex bead assays, ADCD and virus neutralization assays were log10 transformed prior to IgG1 normalization. MFI = median fluorescent intensity; \* = p < 0.05; \*\* = p < 0.01; \*\*\* = p < 0.001. 355

It is made available under a CC-BY 4.0 International license .

#### 357 **4. Discussion**

358 SARS-CoV-2 vaccination has been suggested to primarily protect against symptomatic or severe disease 359 rather than preventing infection altogether (17). Consequently, vaccinations are mainly recommended for 360 individuals at high risk for severe COVID-19, such as those over 60 years old, immunocompromised 361 individuals, or healthcare workers interacting with high-risk groups (3). Previous studies with a similar 362 aim, but no exposure documentation, have highlighted the importance of nAbs in disease prevention (18-363 20). This study aimed to determine whether any serological parameters of acquired immunity may predict 364 protection from breakthrough infections. A previous study showed that healthcare workers with 365 breakthrough SARS-CoV-2 infections has significantly lower IgG antibody titers, but showed substantial 366 overlaps between groups (21). However, they did not document the exposure of study participants to the 367 virus, it remained unclear if participants who remained negative were protected by their adaptive immune response or merely unexposed to the virus. Another study that was conducted in Israel in 2021 tested 368 369 people exposed to a SARS-CoV-2-positive contact in their household during the Delta wave. This study 370 identified nAb and IgG titers as CoPs against breakthrough infection, with some outliers that were 371 infected even when antibody titers were rather high. However, that study tested only antibodies against 372 the ancestral spike antigen, and not the Delta variants, which was in circulation at the time (22).We 373 conducted our study with households containing a SARS-CoV-2 positive index person, who acted as the 374 disease transmitter and assessed serology in a variant specific manner. Household members provided 375 blood samples within 24 hours and were monitored for infection and symptoms for 14 days thereafter, 376 upon which they donated a blood sample again. Serum features of targeted responses to ancestral, 377 Omicron BA.1 or BA.5 spike antigen were performed, including nAbs.

378 The analysis of approximately 200 features in the serum samples from the early time point revealed 22 379 significantly differentially expressed markers in our study. Half of these markers were related to Ig 380 subtypes, as for instance IgG1 and IgA, or nAbs titers. A similar study conducted in Israel with 1,461 381 household members in 2021, when the Delta variant was dominant, found results consistent with ours, 382 identifying IgG titers and nAbs as correlates of protection against infection and disease severity (22). 383 However, that study did not comprehensively address parameters of antibody responses in a virus variant 384 specific manner. Hence, the ability of antibodies to neutralize the Delta variant were not assessed. Our 385 study shows that neutralization assays against the ancestral variant are less accurate in predicting the 386 protection against infection than those based on antigens from contemporary circulating virus variants. 387 While antibodies against pre-Alpha spike antigen were still significantly upregulated in individuals who 388 remained uninfected, the ROC analysis revealed that their predictive accuracy was inferior to those of 389 closely related variants.

It is made available under a CC-BY 4.0 International license .

390 Importantly, both groups in our study were similar in terms of vaccination status or time elapsed since the 391 last immunogenic event. This suggests that the time since the last vaccination is a rather crude predictor 392 of protection against breakthrough infections. On the other hand, neutralizing titers against a close variant 393 were a very robust correlate of protection, especially among people with no immunological evidence of a 394 recent infection. We propose that our results argue for two important ideas. Firstly, our data argue that 395 high neutralizing titers may protect against any breakthrough infection, and thus impede the transmission. 396 Therefore, a high antibody titer induced by a fresh booster shot would prevent not only disease, but also 397 break the chain of transmission. Secondly, our data provide evidence that eliciting high neutralizing titers 398 among caregivers of immunocompromised people would limit the spread of the virus to the vulnerable 399 and thus protect the population at risk. Consequently, we propose that regular assessments of neutralizing 400 antibody titers of medical personnel and caregivers working in senior foster care would identify those 401 who need additional booster shots to protect indirectly the very vulnerable population, whose immune 402 system is weak and frequently subject to vaccine failure.

403 Since some participants were already infected at the initial time point, we investigated the impact of IgM 404 on neutralization. We observed that IgM levels were elevated in several study participants, indicating 405 recent exposure to the virus. Excluding the participants with high IgM levels from the analysis revealed a 406 remarkably strong differentiation in nAb concentrations between positive and negative household 407 members. This suggests that individuals with high IgM levels may skew the predictive value of nAbs as a 408 correlate of protection. To explore this further, we also depleted IgM using 2-ME and repeated the 409 neutralization assay (13). Overall, no significant differences were observed compared to the IgM-410 containing assays. This finding aligns with the results of Klingler et al., who demonstrated that IgM and 411 IgG are both important for virus neutralization (23). We propose that the participants with high IgM had 412 high neutralization efficacy due to recent infections and that any serological diagnostics for CoP needs to 413 include IgM testing to identify people with a recent exposure to the virus.

414 Our study has several limitations. We performed exhaustive immunological analyses on samples from a 415 rather small cohort. In consequence, the statistical power was low and some of the features that were 416 classified as non-significant may well differ between people who are protected against a household 417 transmission and those who are not. The low statistical power also limits our ability to define quantitative 418 thresholds in antibody titers needed for protection. Moreover, since we used a neutralization assay 419 performed with pseudotyped viruses, the standardization of this assay for quantitative purposes may 420 present technical challenges. We did not interview the household member about their behavior, such as 421 isolation from the index case, and we did not perform PCR analyses on a daily basis, thus potentially 422 omitting cases that resolved very rapidly. Additionally, our study was conducted in late 2022, during the

It is made available under a CC-BY 4.0 International license .

423 prevalence of the Omicron BA.4/5 variant, prior to the emergence of currently circulating variants.

- 424 Hence, a similar study performed on samples from current and upcoming variants is required to solidify
- 425 our conclusions.
- 426 Nevertheless, our findings demonstrate that nAb concentrations strongly correlate with protection against
- 427 SARS-CoV-2 infection. Contrary to current vaccination recommendations, we propose that serology
- 428 testing for nAbs and boosting those with low concentrations may prevent not only disease manifestations,
- 429 but also effectively block transmission. Notably, testing with the variant that is currently prevalent
- 430 provides high accuracy, eliminating the need for an index person-specific test and simplifying this
- 431 diagnostic approach.

It is made available under a CC-BY 4.0 International license .

#### 432 Funding

- 433 This research was funded by the Impulse and Networking fund of the Helmholtz Association through the
- 434 grant PIE-0008 to LCS and VH-NG-19-28 to YCB and by the Deutsche Forschungsgemeinschaft (DFG,
- 435 German Research Foundation) under Germany's Excellence Strategy EXC 2155 project number
- 436 390874280 to LCS. BL and MH received funding within the RESPINOW project from the Federal
- 437 Ministry of Education and Research under the grant number 031L0298A

# 438 Acknowledgement

- We gratefully acknowledge Denise Clesle, Ayse Barut and Yuliia Polianska for technical support,
  Natascha Gödecke for administrative support with regulatory affairs and compliance and Henning
  Jacobsen for technical advice and discussions. IH was supported by the Hannover Biomedical Research
- 442 School (HBRS) and the Center for Infection Biology (ZIB), Germany.

#### 443 Author contribution

- 444 Conceptualization: H.M., M.L., M.H., B.L., M.P. and L.C.-S.; investigation: H.M., I.H., M.L., T.P., N.B.
- 445 and R.E.; formal analysis: H.M., I.H. and L.C.-S.; resources: M.L. and M.P.; data curation: H.M. and
- 446 L.C.-S.; writing original draft preparation: H.M.; writing review and editing: L.C.-S.; supervision:
- 447 M.L. and L.C.-S.; funding acquisition: Y.B. and L.C.-S. All authors have read and agreed to the published
- 448 version of the manuscript.

#### 449 Data availability

450 The dataset used is available in the supplementary file and from the corresponding author on reasonable 451 request.

# 452 Competing interests

453 BL is a member of the Expert Council 'Health and Resilience', Federal Chancellery, as well as a member 454 of the Standing Vaccination Commission at the Robert Koch Institute. BL is the elected (Deputy) 455 President of the German Society for Epidemiology (DGEpi), deputy in 2023 and 2026, president in 2024 456 and 2025 and part of the pool of experts of the Federal Ministry of Education and Research (BMBF) for 457 consultations on pandemic preparedness and the overall responsiveness of health research to health crises. 458 BL is also a member of the Advisory Board for the Pact for Public Health (Pakt ÖGD), Federal Ministry 459 of Health (BMG), an elected Speaker of the Modelling Network for Severe Infectious Diseases in 460 Germany (MONID), a member of the DZIF Internal Advisory Board, and an elected member of the 461 steering committee of TBNet. All other authors state that there is no competing interest.

It is made available under a CC-BY 4.0 International license .

### 462 **References**

463 1. Makhluf H, Madany H, Kim K. Long COVID: Long-Term Impact of SARS-CoV2. Diagnostics
464 (Basel). 2024;14(7).

- Ssentongo P, Ssentongo AE, Voleti N, Groff D, Sun A, Ba DM, et al. SARS-CoV-2 vaccine
  effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-
- 467 analysis. BMC Infect Dis. 2022;22(1):439.
- 468 3. Health FMo. Information on coronavirus vaccination. 2024.
- 469 4. Catala M, Mercade-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, et al. The effectiveness of
  470 COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK,

471 Spain, and Estonia. Lancet Respir Med. 2024;12(3):225-36.

- Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, highthroughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods.
  2011;366(1-2):8-19.
- Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2
  infection and COVID-19 disease. Immunol Rev. 2022;310(1):6-26.
- Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
  antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
  Nature medicine. 2021;27(7):1205-11.
- 480 8. Goguet E, Olsen CH, Meyer WA, 3rd, Ansari S, Powers JH, 3rd, Conner TL, et al. Immune and
  481 behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection. Front
  482 Immunol. 2024;15:1287504.
- Martin Perez C, Aguilar R, Jimenez A, Salmeron G, Canyelles M, Rubio R, et al. Correlates of
  protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
  BMC Med. 2024;22(1):103.
- Pavletic M, Mazor M, Lerga M, Mileta T, Zeleznjak J, Ruzic T, et al. Fast, Reliable, and Simple
  Point-of-Care-like Adaptation of RT-qPCR for the Detection of SARS-CoV-2 for Use in Hospital
  Emergency Departments. Viruses. 2021;13(12).
- 489 11. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of
  490 epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evolution. 2021;7(2).
- 491 12. Katzmarzyk M, Clesle DC, van den Heuvel J, Hoffmann M, Garritsen H, Pöhlmann S, et al.
- 492 Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants
   493 on the neutralization capacity of post-vaccination sera. Front Immunol. 2023;14:1288794.
- 494 13. Capel PJ, Gerlag PG, Hagemann JF, Koene RA. The effect of 2-mercaptoethanol on IgM and IgG
  495 antibody activity. J Immunol Methods. 1980;36(1):77-80.
- 496 14. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, et al. High-throughput,
- 497 multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods.
   498 2012;386(1-2):117-23.
- Fischinger S, Fallon JK, Michell AR, Broge T, Suscovich TJ, Streeck H, et al. A high-throughput,
  bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J
  Immunol Methods. 2019;473:112630.
- 502 16. Karsten CB, Mehta N, Shin SA, Diefenbach TJ, Slein MD, Karpinski W, et al. A versatile high-
- throughput assay to characterize antibody-mediated neutrophil phagocytosis. J Immunol Methods.
   2019;471:46-56.
- The State of Stat
- 18. Atti A, Insalata F, Carr EJ, Otter AD, Foulkes S, Wu MY, et al. Antibody correlates of protection
- against Delta infection after vaccination: A nested case-control within the UK-based SIREN study. J
- 509 Infect. 2023.

- 510 19. Martín Pérez C, Aguilar R, Jiménez A, Salmerón G, Canyelles M, Rubio R, et al. Correlates of
- protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
  BMC Medicine. 2024;22(1):103.
- 513 20. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al. Neutralizing
- Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak
  with a High Attack Rate. J Clin Microbiol. 2020;58(11).
- 515 with a High Attack Rate. J Clin Microbiol. 2020;58(11).
- 516 21. Möhlendick B, Čiučiulkaitė I, Elsner C, Anastasiou OE, Trilling M, Wagner B, et al. Individuals
- With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough
   Infections. Front Immunol. 2022;13:907343.
- 519 22. Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, et al. Correlates of protection
- 520 against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to
- 521 SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe.
- 522 2023;4(5):e309-e18.
- 523 23. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, et al. Role of IgM and IgA
- 524 Antibodies in the Neutralization of SARS-CoV-2. medRxiv. 2020.